BRPI1013428A2 - anticorpos humanizados para axl - Google Patents

anticorpos humanizados para axl

Info

Publication number
BRPI1013428A2
BRPI1013428A2 BRPI1013428A BRPI1013428A BRPI1013428A2 BR PI1013428 A2 BRPI1013428 A2 BR PI1013428A2 BR PI1013428 A BRPI1013428 A BR PI1013428A BR PI1013428 A BRPI1013428 A BR PI1013428A BR PI1013428 A2 BRPI1013428 A2 BR PI1013428A2
Authority
BR
Brazil
Prior art keywords
axl
humanized antibodies
humanized
antibodies
bind
Prior art date
Application number
BRPI1013428A
Other languages
English (en)
Inventor
Ruhe Jens
Wirtz Peter
Takizawa Takeshi
Takayama Tomoko
Original Assignee
U3 Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP09006355A external-priority patent/EP2270053A1/en
Application filed by U3 Pharma Gmbh filed Critical U3 Pharma Gmbh
Publication of BRPI1013428A2 publication Critical patent/BRPI1013428A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

anticorpos humanizados para axl a presente invenção refere-se a anticorpos monoclonais humanizados que se ligam ao domínio extracelular de axl e pelo menos parcial- 5 mente inibam a atividade de axl.
BRPI1013428A 2009-05-11 2010-05-11 anticorpos humanizados para axl BRPI1013428A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09006355A EP2270053A1 (en) 2009-05-11 2009-05-11 Humanized AXL antibodies
EP09006474 2009-05-13
PCT/EP2010/056487 WO2010130751A1 (en) 2009-05-11 2010-05-11 Humanized axl antibodies

Publications (1)

Publication Number Publication Date
BRPI1013428A2 true BRPI1013428A2 (pt) 2019-07-02

Family

ID=42272537

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1013428A BRPI1013428A2 (pt) 2009-05-11 2010-05-11 anticorpos humanizados para axl

Country Status (15)

Country Link
US (2) US8841424B2 (pt)
EP (1) EP2430050A1 (pt)
JP (2) JP5909442B2 (pt)
KR (1) KR20120035145A (pt)
CN (1) CN102421802B (pt)
AR (1) AR076564A1 (pt)
AU (1) AU2010247464B2 (pt)
BR (1) BRPI1013428A2 (pt)
CA (1) CA2759836A1 (pt)
IL (1) IL216147A (pt)
MX (1) MX2011011825A (pt)
RU (2) RU2571224C2 (pt)
TW (2) TW201105348A (pt)
WO (1) WO2010130751A1 (pt)
ZA (1) ZA201107529B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201105348A (en) * 2009-05-11 2011-02-16 U3 Pharma Gmbh Humanized axl antibodies
US9005926B2 (en) 2009-10-02 2015-04-14 Biogen Idec Ma Inc. Methods of preventing and removing trisulfide bonds
JP6236383B2 (ja) 2011-05-13 2017-11-22 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． トリスルフィド結合を防止および除去する方法
US9249228B2 (en) * 2011-06-22 2016-02-02 Oribase Pharma Anti-Axl antibodies and uses thereof
JP6120833B2 (ja) * 2011-06-22 2017-04-26 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル）Ｉｎｓｅｒｍ（Ｉｎｓｔｉｔｕｔ Ｎａｔｉｏｎａｌ Ｄｅｌａ Ｓａｎｔｅ Ｅｔ Ｄｅ Ｌａ Ｒｅｃｈｅｒｃｈｅ Ｍｅｄｉｃａｌｅ） 抗Ａｘｌ抗体及びその使用
EP2589609A1 (en) * 2011-11-03 2013-05-08 Pierre Fabre Medicament Antigen binding protein and its use as addressing product for the treatment of cancer
US9879061B2 (en) 2011-12-15 2018-01-30 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis
ES2871815T3 (es) * 2012-11-05 2021-11-02 Pf Medicament Nuevas proteínas de unión a antígeno y su utilización como producto de direccionamiento para el tratamiento del cáncer
JP6345690B2 (ja) * 2012-12-14 2018-06-20 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 改変ａｘｌペプチド及び抗転移療法のａｘｌシグナル伝達阻害におけるその使用
WO2016091891A1 (en) * 2014-12-09 2016-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies against axl
AU2015366213B2 (en) 2014-12-18 2021-10-07 Bergenbio Asa Anti-Axl antagonistic antibodies
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
WO2016187356A1 (en) 2015-05-18 2016-11-24 Agensys, Inc. Antibodies that bind to axl proteins
US10787516B2 (en) 2015-05-18 2020-09-29 Agensys, Inc. Antibodies that bind to AXL proteins
GB201509338D0 (en) 2015-05-29 2015-07-15 Bergenbio As Combination therapy
EP3319993B1 (en) 2015-07-10 2020-01-15 Genmab A/S Axl-specific antibody-drug conjugates for cancer treatment
MX2018003594A (es) 2015-09-24 2018-06-15 Daiichi Sankyo Co Ltd Anticuerpo anti-garp.
SG11201808994YA (en) * 2016-04-15 2018-11-29 Bioatla Llc Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof
GB201610902D0 (en) 2016-06-22 2016-08-03 Bergen Teknologioverforing As And Bergenbio As Anti-Axl Antagonistic Antibodies
KR20190141666A (ko) 2017-04-20 2019-12-24 에이디씨 테라퓨틱스 에스에이 항-axl 항체-약물 접합체로의 병용 요법
CN110540592B (zh) * 2018-05-29 2022-08-09 杭州尚健生物技术有限公司 结合axl蛋白的抗体及其应用
CN109160941B (zh) * 2018-09-29 2020-09-04 未名生物医药有限公司 蛋白序列17e11及其用途
RU2678569C1 (ru) * 2018-10-31 2019-01-30 Гордейчук Владимир Евгеньевич Способ подавления метастазирования опухолей
GB201912059D0 (en) 2019-08-22 2019-10-09 Bergenbio As Combaination therapy of a patient subgroup
CN110982791A (zh) * 2019-12-26 2020-04-10 百泰生物药业有限公司 一种分泌axl抗体的杂交瘤细胞的制备筛选方法
CA3164037A1 (en) 2020-01-08 2021-07-15 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
GB202004189D0 (en) 2020-03-23 2020-05-06 Bergenbio As Combination therapy
US20230250169A1 (en) 2020-04-08 2023-08-10 Bergenbio Asa AXL Inhibitors for Antiviral Therapy
GB202006072D0 (en) 2020-04-24 2020-06-10 Bergenbio Asa Method of selecting patients for treatment with cmbination therapy
GB202104037D0 (en) 2021-03-23 2021-05-05 Bergenbio Asa Combination therapy
CN116715774B (zh) * 2023-05-12 2023-11-24 武汉爱博泰克生物科技有限公司 针对人axl的兔单克隆抗体及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931385A (en) * 1985-06-24 1990-06-05 Hygeia Sciences, Incorporated Enzyme immunoassays and immunologic reagents
DE3900534A1 (de) 1989-01-10 1990-07-12 Boehringer Mannheim Gmbh Diagnostischer nachweis unter verwendung von chimaeren antikoerpern
US5468634A (en) * 1991-06-24 1995-11-21 The University Of North Carolina At Chapel Hill Axl oncogene
EP0939653B1 (en) * 1996-03-20 2005-08-31 Immunomedics, Inc. Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications
EP1190061A1 (en) 1999-06-07 2002-03-27 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
EP1382969A1 (en) * 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
EP2385069A3 (en) 2003-11-12 2012-05-30 Biogen Idec MA Inc. Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
WO2006037604A1 (en) * 2004-10-01 2006-04-13 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Novel antibodies directed to the mammalian eag1 ion channel protein
PT2620450T (pt) 2005-03-08 2018-12-17 Pfizer Prod Inc Composições de anticorpos anti-ctla-4
US20100104564A1 (en) 2005-03-29 2010-04-29 Genevieve Hansen Altered Antibody Fc Regions and Uses Thereof
KR101539545B1 (ko) 2005-06-07 2015-07-24 에스바테크 - 어 노바티스 컴파니 엘엘씨 ＴＮＦα를 억제하는 안정적이고 가용성인 항체
JP2010532360A (ja) 2007-07-02 2010-10-07 ワイス・エルエルシー 骨障害の処置における使用のためのａｘｌのモジュレーター
EP2217716A4 (en) * 2007-11-09 2011-02-09 Salk Inst For Biological Studi USE OF TAM RECEPTOR INHIBITORS AS ANTIMICROBIAL AGENTS
CN101939336B (zh) * 2007-11-12 2014-05-14 U3制药有限公司 Axl抗体
TW201105348A (en) * 2009-05-11 2011-02-16 U3 Pharma Gmbh Humanized axl antibodies

Also Published As

Publication number Publication date
TW201509431A (zh) 2015-03-16
CN102421802B (zh) 2014-08-20
AU2010247464B2 (en) 2014-09-11
US20120117670A1 (en) 2012-05-10
RU2011150183A (ru) 2013-06-20
US8841424B2 (en) 2014-09-23
MX2011011825A (es) 2011-12-06
RU2571224C2 (ru) 2015-12-20
JP2012526530A (ja) 2012-11-01
JP5909442B2 (ja) 2016-04-26
KR20120035145A (ko) 2012-04-13
AU2010247464A1 (en) 2011-11-10
JP2016011306A (ja) 2016-01-21
EP2430050A1 (en) 2012-03-21
WO2010130751A1 (en) 2010-11-18
CA2759836A1 (en) 2010-11-18
RU2015147287A (ru) 2017-05-12
AR076564A1 (es) 2011-06-22
TWI526223B (zh) 2016-03-21
US20150037323A1 (en) 2015-02-05
IL216147A (en) 2016-04-21
IL216147A0 (en) 2012-01-31
ZA201107529B (en) 2012-06-27
CN102421802A (zh) 2012-04-18
TW201105348A (en) 2011-02-16

Similar Documents

Publication Publication Date Title
BRPI1013428A2 (pt) anticorpos humanizados para axl
CY1121349T1 (el) Συζευγματα αντισωματων πυρρολοβενζοδιαζεπινης
CR20120577A (es) Anticuerpos hacia gdf8 humano
CR20150054A (es) Anticuerpos anti-cxcr5 humanizados derivados de los mismos y su uso
CL2014000574A1 (es) Anticuerpo monoclonal humanizado que se une al complejo aßtcr/cd3 humano.
BR112016000666A2 (pt) Constructos de ligação de antígeno cd3 e cd19 biespecíficos
CR20140146A (es) Anticuerpos anti-cd134 (ox40) y usos de los mismos
HN2006015949A (es) Anticuerpos de p-caderina
CR20150284A (es) Terapia de combinación de anticuerpos anti-her3 y anti-her2
CU24446B1 (es) Un anticuerpo monoclonal humanizado que se une a tau
CL2013001287A1 (es) Glucocorticoides para tratar, mejorar o profilaxis de los efectos adversos neurológicos causados por un diminio de unión cd3; kit que comprende un gc y un dominio de unión cd3 y las instrucciones.
CO6280499A2 (es) Anticuerpos monoclonales, los cuales enlazan al dominio extracelular del receptor axl de tirosina quinasa y los cuales por lo menos parcialmente inhiben la actividad axl
CO6551674A2 (es) Anticuerpos anti-her3 y usos de los mismo
CO6690763A2 (es) Anticuerpo específico de miostatina y composiciones que lo contienen
SMT201400184B (it) Anticorpi monoclonali che legano b7h6 e loro usi
CR11465A (es) Anticuerpos bivalentes biespecificos
ECSP10010270A (es) Anticuerpos bivalentes biespecíficos
EA201790664A1 (ru) Антитела против мезотелина и иммуноконъюгаты
MX2011011925A (es) Anticuerpos triespecificos o tetraespecificos.
SG10201703798YA (en) Antibodies with modified affinity to fcrn that promote antigen clearance
BRPI1010297A2 (pt) anticorpos biespecíficos trivalentes.
CR20110559A (es) Anticuerpos específicos para cadherina-17
MX2011013717A (es) Anticuerpos anti notch-1.
BRPI0809665B8 (pt) anticorpo monoclonal que se liga especificamente a endosialina
MX352599B (es) Anticuerpos anti-receptor tipo proteina-tirosina-fosfatasa sigma humano.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2531 DE 09-07-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]